

Supplementary Information

Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors

Rien Ritawidya ^{1,2,*}, Friedrich-Alexander Ludwig ¹, Detlef Briel ³, Peter Brust ¹ and
Matthias Scheunemann ^{1,*}

¹ Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceuticals Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Leipzig 04318, Germany

² Center for Radioisotope and Radiopharmaceutical Technology, National Nuclear and Energy Agency (BATAN), Puspitpek Area, Serpong, South Tangerang, Indonesia

³ Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Faculty of Medicine, Leipzig University, Brüderstraße 34, Leipzig 04103, Germany

* Correspondence: r.ritawidya@hzdr.de or rienrita@batan.go.id; m.scheunemann@hzdr.de (M.S.); Tel.: +49-341-234-179-4611 (R.R.); +49-341-234-179-4618 (M.S.)

Table of Contents

Images of ¹ H-NMR spectrum and HRMS (ESI) of final compounds	S3
Figure S1. A. ¹ H-NMR (400 MHz, CDCl ₃), B. ¹³ C-NMR (75 MHz, CDCl ₃) spectrum of BIT1	S4
Figure S2. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT1	S5
Figure S3. A. ¹ H-NMR (400 MHz, CDCl ₃), B. ¹³ C-NMR (101 MHz, CDCl ₃) spectrum of BIT2	S6
Figure S4. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum, of BIT2	S7
Figure S5. A. ¹ H-NMR (400 MHz, CDCl ₃), B. ¹³ C-NMR (101 MHz, CDCl ₃) spectrum of BIT3	S8
Figure S6. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT3	S9
Figure S7. A. ¹ H-NMR (400 MHz, CDCl ₃), B. ¹³ C-NMR (75 MHz, CDCl ₃) spectrum of BIT4	S10
Figure S8. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT4	S11
Figure S9. A. ¹ H-NMR (300 MHz, CDCl ₃), B. ¹³ C-NMR (75 MHz, CDCl ₃) spectrum of BIT5	S12
Figure S10. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT5	S13
Figure S11. A. ¹ H-NMR (300 MHz, CDCl ₃), B. ¹³ C-NMR (75 MHz, CDCl ₃) spectrum of BIT6	S14
Figure S12. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT6	S15
Figure S13. A. ¹ H-NMR (400 MHz, CDCl ₃), B. ¹³ C-NMR (101 MHz, CDCl ₃) spectrum of BIT7	S16
Figure S14. A. ¹⁹ F-NMR (377 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT7	S17
Figure S15. A. ¹ H-NMR (300 MHz, CDCl ₃), B. ¹³ C-NMR (75 MHz, CDCl ₃) spectrum of BIT8	S18
Figure S16. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT8	S19
Figure S17. A. ¹ H-NMR (300 MHz, CDCl ₃), B. ¹³ C-NMR (101 MHz, CDCl ₃) spectrum of BIT9	S20
Figure S18. A. ¹⁹ F-NMR (282 MHz, CDCl ₃), B. HRMS (ESI+) spectrum of BIT9	
2. In vitro evaluation (Dose Response Curve) (SB Drug Discovery-Scotland)	
Figure S19. A. BIT1 , BIT6 , BIT9 towards PDE2A and PDE10A, B. BAY60-7550 and TA1 towards PDE2A	S21




Figure S1. A. ^1H -NMR and B. ^{13}C -NMR spectrum of BIT1 in CDCl_3





Figure S2. A. ^{19}F -NMR spectrum of **BIT1** in CDCl_3 and **B.** HRMS (ESI+) spectrum of **BIT1**

Figure S3. A. ¹H-NMR and B. ¹³C-NMR spectrum of BIT2 in CDCl₃





Figure S4. A. ^{19}F -NMR spectrum of **BIT2** in CDCl_3 and B. HRMS (ESI+) spectrum of **BIT2**







Figure S6. A. ^{19}F -NMR spectrum of **BIT3** in CDCl_3 , **B.** HRMS (ESI+) spectrum of **BIT3**






Figure S8. A. ^{19}F -NMR spectrum of BIT4 in CDCl_3 , **B.** HRMS (ESI+) spectrum of BIT4




Figure S9. A. ^1H -NMR and B. ^{13}C -NMR spectrum of BIT5 in CDCl_3





Figure S10. A. ^{19}F -NMR spectrum of BIT5 in CDCl_3 , **B.** HRMS (ESI+) spectrum of BIT5

Figure S11. A. ^1H -NMR and B. ^{13}C -NMR spectrum of BIT6 in CDCl_3





Figure S12. A. ^{19}F -NMR spectrum of **BIT6** in CDCl_3 , **B.** HRMS (ESI+) spectrum of **BIT6**

Figure S13. A. ¹H-NMR and B. ¹³C-NMR spectrum of BIT7 in CDCl₃





Figure S14. A. ^{19}F -NMR spectrum of **BIT7** in CDCl_3 , **B.** HRMS (ESI+) spectrum of **BIT7**

Figure S15. A. ^1H -NMR and B. ^{13}C -NMR spectrum of BIT8 in CDCl_3





Figure S16. A. ^{19}F -NMR spectrum of **BIT8** in CDCl_3 , **B.** HRMS (ESI+) spectrum of **BIT8**

Figure S17. A. ¹H-NMR spectrum of BIT9 in CDCl₃ and B. ¹³C-NMR spectrum of BIT9





Figure S18. A. ^{19}F -NMR spectrum of **BIT9** in CDCl_3 , **B.** HRMS (ESI+) spectrum of **BIT9**

2. In vitro evaluation (Dose Response Curve) (SB Drug Discovery-Scotland)

A.



B.




Figure S19. A. BIT1, BIT6, BIT9 towards PDE2A and PDE10A, B. BAY 60-7550 and TA1 towards PDE2A